![Kirsty McCarthy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Posizioni attive di Kirsty McCarthy
Società | Posizione | Inizio | Fine |
---|---|---|---|
Pathios Therapeutics Ltd.
![]() Pathios Therapeutics Ltd. BiotechnologyHealth Technology Pathios Therapeutics Ltd. engages in discovering and developing novel small molecule drugs. The company was founded by Thomas David McCarthy, Alan Naylor, Kirsty McCarthy, Peter Joyce and Someit Sidhu in 2017 and is headquartered in Oxford, the United Kingdom. | Direttore operativo | 01/01/2017 | - |
Fondatore | 01/01/2017 | - | |
Grey Wolf Therapeutics Ltd.
![]() Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | Direttore operativo | - | - |
Storia della carriera di Kirsty McCarthy
Statistiche
Distribuzione geografica
Regno Unito | 3 |
Posizioni
Chief Operating Officer | 2 |
Founder | 1 |
Settori
Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
Pathios Therapeutics Ltd.
![]() Pathios Therapeutics Ltd. BiotechnologyHealth Technology Pathios Therapeutics Ltd. engages in discovering and developing novel small molecule drugs. The company was founded by Thomas David McCarthy, Alan Naylor, Kirsty McCarthy, Peter Joyce and Someit Sidhu in 2017 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Grey Wolf Therapeutics Ltd.
![]() Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Kirsty McCarthy
- Esperienza